Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 35, Issue 6, Pages 747–752
Research Article

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer

1Department of Experimental and Clinical Sciences, “G. D’Annunzio” University, 66100 Chieti, Italy
2MediaPharma s.r.l., Via dei Vestini 31, 66100 Chieti, Italy
3Eventus Diagnostics, Inc., Jehuda Hills, 90880 Ora, Israel

Received 8 July 2013; Revised 11 October 2013; Accepted 11 October 2013

Academic Editor: Grant Izmirlian

Copyright © 2013 Antonino Grassadonia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Purpose. Circulating autoantibodies have been extensively investigated as possible markers for early diagnosis of cancer. The present study was carried out to investigate whether anti-LGALS3BP IgG autoantibodies could be classified as a biomarker for malignant tumors. Methods. An in-house developed enzyme-linked immunosorbent assay was used to detect autoantibodies to LGALS3BP in sera from 71 patients with various types of cancers and 54 healthy subjects matched by age and gender. Results. Patients with cancer have significant higher circulating levels of anti-LGALS3BP antibodies as compared to control subjects ( ). The test has a sensitivity of 33% and a specificity of 98%. Conclusions. Anti-LGALS3BP IgG autoantibodies are a promising biomarker for malignant tumors and could play a role in the development of a multimarker assay for the early detection of cancer.